Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 76 | 2021 | 274 | 11.040 |
Why?
|
| Anti-Asthmatic Agents | 12 | 2020 | 39 | 2.640 |
Why?
|
| Adrenal Cortex Hormones | 14 | 2021 | 123 | 2.020 |
Why?
|
| Severity of Illness Index | 28 | 2021 | 922 | 1.910 |
Why?
|
| Phenotype | 24 | 2021 | 657 | 1.830 |
Why?
|
| Sputum | 9 | 2021 | 17 | 1.360 |
Why?
|
| Bronchodilator Agents | 12 | 2021 | 49 | 1.240 |
Why?
|
| Lung | 12 | 2021 | 279 | 1.150 |
Why?
|
| Bronchoscopy | 4 | 2019 | 56 | 0.990 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2021 | 154 | 0.990 |
Why?
|
| Eosinophils | 10 | 2021 | 32 | 0.970 |
Why?
|
| Forced Expiratory Volume | 19 | 2020 | 92 | 0.860 |
Why?
|
| Adult | 50 | 2021 | 10030 | 0.800 |
Why?
|
| Cluster Analysis | 6 | 2019 | 128 | 0.780 |
Why?
|
| Humans | 79 | 2021 | 34562 | 0.770 |
Why?
|
| Neutrophils | 5 | 2020 | 123 | 0.770 |
Why?
|
| Adolescent | 29 | 2020 | 3805 | 0.710 |
Why?
|
| Male | 56 | 2021 | 20740 | 0.680 |
Why?
|
| Respiratory Function Tests | 14 | 2021 | 105 | 0.680 |
Why?
|
| Female | 56 | 2021 | 21532 | 0.670 |
Why?
|
| Dyspnea | 2 | 2019 | 36 | 0.630 |
Why?
|
| Cough | 1 | 2019 | 21 | 0.600 |
Why?
|
| Middle Aged | 38 | 2021 | 12726 | 0.590 |
Why?
|
| Biological Products | 1 | 2020 | 80 | 0.580 |
Why?
|
| Young Adult | 19 | 2020 | 2831 | 0.570 |
Why?
|
| Bronchi | 7 | 2021 | 41 | 0.560 |
Why?
|
| Leukocyte Count | 5 | 2020 | 50 | 0.550 |
Why?
|
| Hypersensitivity | 2 | 2017 | 26 | 0.530 |
Why?
|
| Glucocorticoids | 5 | 2020 | 154 | 0.530 |
Why?
|
| Albuterol | 6 | 2019 | 19 | 0.530 |
Why?
|
| Immunologic Factors | 1 | 2017 | 54 | 0.510 |
Why?
|
| Immunotherapy | 1 | 2017 | 96 | 0.500 |
Why?
|
| Child | 22 | 2019 | 2614 | 0.490 |
Why?
|
| Smoking | 2 | 2021 | 544 | 0.490 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2020 | 62 | 0.470 |
Why?
|
| Administration, Inhalation | 11 | 2019 | 56 | 0.460 |
Why?
|
| Polymorphism, Single Nucleotide | 13 | 2020 | 1079 | 0.440 |
Why?
|
| Immunoglobulin E | 8 | 2020 | 36 | 0.440 |
Why?
|
| Cohort Studies | 13 | 2021 | 1910 | 0.410 |
Why?
|
| Receptors, Adrenergic, beta-2 | 4 | 2019 | 25 | 0.380 |
Why?
|
| Aged | 19 | 2021 | 11022 | 0.360 |
Why?
|
| Granulocytes | 3 | 2021 | 13 | 0.350 |
Why?
|
| European Continental Ancestry Group | 9 | 2019 | 1176 | 0.340 |
Why?
|
| Nitric Oxide | 7 | 2019 | 124 | 0.310 |
Why?
|
| Practice Guidelines as Topic | 3 | 2012 | 431 | 0.310 |
Why?
|
| Alendronate | 2 | 2019 | 11 | 0.300 |
Why?
|
| Epithelial Cells | 3 | 2019 | 148 | 0.290 |
Why?
|
| Genome-Wide Association Study | 5 | 2016 | 555 | 0.280 |
Why?
|
| African Americans | 8 | 2019 | 1435 | 0.270 |
Why?
|
| Inflammation | 4 | 2021 | 557 | 0.270 |
Why?
|
| Adrenergic beta-Agonists | 4 | 2019 | 36 | 0.270 |
Why?
|
| Gene Expression | 3 | 2021 | 363 | 0.260 |
Why?
|
| Age of Onset | 4 | 2012 | 95 | 0.250 |
Why?
|
| Cytokines | 2 | 2020 | 269 | 0.250 |
Why?
|
| Longitudinal Studies | 5 | 2021 | 803 | 0.250 |
Why?
|
| Interleukin-5 | 2 | 2020 | 7 | 0.240 |
Why?
|
| Comorbidity | 5 | 2019 | 596 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2019 | 926 | 0.230 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 3 | 2019 | 16 | 0.230 |
Why?
|
| Disease Progression | 2 | 2017 | 634 | 0.220 |
Why?
|
| Age Factors | 5 | 2017 | 1262 | 0.210 |
Why?
|
| Breath Tests | 6 | 2019 | 18 | 0.210 |
Why?
|
| Respiratory Mucosa | 2 | 2021 | 12 | 0.210 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 4157 | 0.210 |
Why?
|
| United States | 11 | 2019 | 4278 | 0.190 |
Why?
|
| Sex Factors | 2 | 2018 | 708 | 0.190 |
Why?
|
| Scopolamine Derivatives | 2 | 2013 | 5 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 326 | 0.180 |
Why?
|
| Double-Blind Method | 7 | 2019 | 597 | 0.180 |
Why?
|
| Prospective Studies | 5 | 2019 | 2463 | 0.180 |
Why?
|
| Vital Capacity | 4 | 2020 | 43 | 0.180 |
Why?
|
| Arginine | 2 | 2012 | 23 | 0.170 |
Why?
|
| Drug Resistance | 2 | 2020 | 42 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2019 | 258 | 0.160 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2020 | 23 | 0.160 |
Why?
|
| Interleukin-5 Receptor alpha Subunit | 1 | 2020 | 1 | 0.160 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2010 | 51 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2019 | 771 | 0.160 |
Why?
|
| Progesterone Reductase | 1 | 2020 | 2 | 0.160 |
Why?
|
| Steroid Isomerases | 1 | 2020 | 2 | 0.160 |
Why?
|
| Leukocytes | 1 | 2020 | 61 | 0.160 |
Why?
|
| Multienzyme Complexes | 1 | 2020 | 20 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 177 | 0.150 |
Why?
|
| Triamcinolone | 1 | 2019 | 12 | 0.150 |
Why?
|
| Influenza Vaccines | 2 | 2010 | 90 | 0.150 |
Why?
|
| Aging | 2 | 2016 | 1010 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 849 | 0.150 |
Why?
|
| Obesity | 4 | 2021 | 1246 | 0.150 |
Why?
|
| Pulmonary Emphysema | 1 | 2019 | 23 | 0.150 |
Why?
|
| Respiration Disorders | 1 | 2019 | 7 | 0.150 |
Why?
|
| Glycoproteins | 1 | 2019 | 44 | 0.150 |
Why?
|
| Phosphoproteins | 1 | 2019 | 54 | 0.150 |
Why?
|
| Influenza, Human | 2 | 2010 | 133 | 0.150 |
Why?
|
| Androstadienes | 2 | 2010 | 17 | 0.140 |
Why?
|
| Perioperative Nursing | 1 | 2018 | 2 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2018 | 42 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1607 | 0.140 |
Why?
|
| Death | 1 | 2018 | 53 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 227 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 99 | 0.130 |
Why?
|
| Prednisolone | 1 | 2017 | 9 | 0.130 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2016 | 7 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 526 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2019 | 1355 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 755 | 0.120 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 55 | 0.120 |
Why?
|
| Cross-Over Studies | 4 | 2019 | 100 | 0.120 |
Why?
|
| Risk Factors | 5 | 2021 | 4137 | 0.120 |
Why?
|
| Research | 1 | 2015 | 88 | 0.110 |
Why?
|
| Disease Susceptibility | 2 | 2017 | 62 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2012 | 20 | 0.110 |
Why?
|
| Pregnenediones | 1 | 2014 | 1 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 565 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2014 | 25 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 988 | 0.100 |
Why?
|
| Respiratory Mechanics | 1 | 2013 | 6 | 0.100 |
Why?
|
| Bronchial Provocation Tests | 2 | 2011 | 6 | 0.100 |
Why?
|
| Vitamins | 1 | 2014 | 75 | 0.100 |
Why?
|
| Pneumonia | 1 | 2013 | 70 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 89 | 0.100 |
Why?
|
| Th1 Cells | 1 | 2013 | 25 | 0.100 |
Why?
|
| Skin Tests | 3 | 2010 | 13 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 703 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2013 | 380 | 0.090 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 16 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2021 | 254 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2012 | 49 | 0.090 |
Why?
|
| Hispanic Americans | 3 | 2014 | 948 | 0.080 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 10 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2011 | 44 | 0.080 |
Why?
|
| Acetates | 1 | 2010 | 14 | 0.080 |
Why?
|
| Eosinophilia | 1 | 2010 | 11 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2011 | 192 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 118 | 0.080 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2010 | 5 | 0.080 |
Why?
|
| Quinolines | 1 | 2010 | 29 | 0.080 |
Why?
|
| Th2 Cells | 1 | 2010 | 9 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2010 | 11 | 0.080 |
Why?
|
| Linkage Disequilibrium | 4 | 2012 | 189 | 0.080 |
Why?
|
| Infant | 1 | 2013 | 1123 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2010 | 32 | 0.080 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 24 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2011 | 268 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2011 | 149 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 44 | 0.080 |
Why?
|
| Discriminant Analysis | 1 | 2009 | 22 | 0.080 |
Why?
|
| Alleles | 2 | 2020 | 261 | 0.070 |
Why?
|
| Spirometry | 3 | 2019 | 30 | 0.070 |
Why?
|
| Vitamin D | 1 | 2010 | 187 | 0.070 |
Why?
|
| Arginase | 1 | 2008 | 6 | 0.070 |
Why?
|
| Biopsy | 2 | 2020 | 273 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 271 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2021 | 3623 | 0.070 |
Why?
|
| Linear Models | 3 | 2018 | 465 | 0.070 |
Why?
|
| Bronchoconstriction | 1 | 2007 | 3 | 0.070 |
Why?
|
| Airway Resistance | 1 | 2007 | 4 | 0.070 |
Why?
|
| Logistic Models | 3 | 2019 | 808 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 306 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 352 | 0.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 32 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2019 | 480 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2017 | 954 | 0.060 |
Why?
|
| Airway Obstruction | 1 | 2006 | 33 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 189 | 0.060 |
Why?
|
| Prevalence | 2 | 2019 | 1034 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 176 | 0.060 |
Why?
|
| Genotype | 2 | 2020 | 744 | 0.050 |
Why?
|
| Population Groups | 1 | 2004 | 8 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2004 | 23 | 0.050 |
Why?
|
| Ethnic Groups | 1 | 2007 | 483 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1129 | 0.050 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2015 | 16 | 0.050 |
Why?
|
| Metalloendopeptidases | 1 | 2003 | 12 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2016 | 154 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2014 | 170 | 0.050 |
Why?
|
| African Continental Ancestry Group | 1 | 2003 | 367 | 0.050 |
Why?
|
| Mice | 1 | 2008 | 2720 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 69 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 142 | 0.040 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2020 | 2 | 0.040 |
Why?
|
| Haplotypes | 3 | 2006 | 221 | 0.040 |
Why?
|
| Androgens | 1 | 2020 | 32 | 0.040 |
Why?
|
| Macrophages, Alveolar | 1 | 2019 | 12 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 29 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 318 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2019 | 56 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 107 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 59 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 17 | 0.040 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2019 | 15 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 67 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 109 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 30 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2019 | 281 | 0.040 |
Why?
|
| Puberty | 1 | 2018 | 8 | 0.030 |
Why?
|
| Quality of Life | 2 | 2016 | 1032 | 0.030 |
Why?
|
| Family | 1 | 2018 | 123 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 163 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 2016 | 3 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 889 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 20 | 0.030 |
Why?
|
| Chest Pain | 1 | 2019 | 232 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 194 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 14 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 305 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 167 | 0.030 |
Why?
|
| Bacteria | 1 | 2016 | 56 | 0.030 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 2015 | 2 | 0.030 |
Why?
|
| Animals | 1 | 2008 | 8579 | 0.030 |
Why?
|
| Education | 1 | 2015 | 38 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 134 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 168 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 502 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 206 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 542 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 213 | 0.030 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2013 | 4 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 1 | 2013 | 15 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2013 | 29 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 1209 | 0.020 |
Why?
|
| Depression | 1 | 2016 | 458 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 176 | 0.020 |
Why?
|
| Airway Remodeling | 1 | 2011 | 5 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 87 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 48 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2011 | 16 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 3825 | 0.020 |
Why?
|
| Exhalation | 1 | 2010 | 3 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2010 | 33 | 0.020 |
Why?
|
| Beclomethasone | 1 | 2010 | 2 | 0.020 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2010 | 6 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 500 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 74 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 83 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 90 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2011 | 91 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 14 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 165 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 108 | 0.020 |
Why?
|
| Vaccination | 1 | 2010 | 153 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1606 | 0.020 |
Why?
|
| Biological Availability | 1 | 2008 | 23 | 0.020 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2007 | 1 | 0.020 |
Why?
|
| Methacholine Chloride | 1 | 2007 | 2 | 0.020 |
Why?
|
| London | 1 | 2007 | 2 | 0.020 |
Why?
|
| Lung Volume Measurements | 1 | 2007 | 4 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 92 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 204 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 265 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2006 | 30 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 142 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 2353 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 600 | 0.010 |
Why?
|
| Netherlands | 1 | 2003 | 25 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2003 | 13 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 222 | 0.010 |
Why?
|